Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
AnaptysBio reported Q2 2026 results, with Jemperli global net sales at $644M, up 34% YoY. Positive AZUR-1 trial results announced, with FDA decision expected in Feb 2027. Litigation with GSK and Tesaro ongoing, with judgment anticipated by Q1 2027. Quimilza FDA decision targeted for Dec 2026. Collaboration revenue increased 25% YoY, driven by Jemperli royalties. Net income from continuing operations was $177.3M for Q2 2026.
How this was made
The 30-second read
Why it matters
The earnings beat and trial progress provide a fresh catalyst for the stock, while litigation adds downside risk.
Market read
The release offers actionable information for traders focusing on biotech earnings and pipeline milestones.
What to watch
Cash burn and upcoming debt paydown may constrain near‑term liquidity.
Background
AnaptysBio disclosed its Q2 2026 financials, royalty revenue growth, and updates on Jemperli and Quimilza pipelines, plus litigation status.
Ticker impact
AnaptysBio reported Q2 2026 results, new royalty revenue, litigation update and upcoming FDA milestones.
Potential price rise of 5‑10% in the next few trading sessions.
New revenue from Jemperli royalties and positive AZUR‑1 interim data provide fresh catalysts; no prior public disclosure.
Market effects
Biotech royalty and oncology trial sector may see increased investor interest.
U.S. biotech market could see modest uplift.
Limited to companies with similar royalty collaborations.
Counterpoint
Litigation risk with GSK/Tesaro could weigh on valuation if judgment is unfavorable.
Key entities
- CompanyAnaptysBio, Inc.
Biotech firm reporting earnings and pipeline updates.
- PartnerGSK
Collaborator on Jemperli royalties and litigation counterpart.
